| Previous close | 27.70 |
| Open | 0.00 |
| Bid | 26.50 x N/A |
| Ask | 29.10 x N/A |
| Day's range | 27.99 - 27.99 |
| 52-week range | 25.21 - 37.80 |
| Volume | |
| Avg. volume | 98,877 |
| Market cap | 169.64B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 7.44 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.64 (5.31%) |
| Ex-dividend date | 08 Nov 2023 |
| 1y target est | N/A |
- Barrons.com
GSK Will Pay Up to $1.5 Billion for CureVac’s mRNA Vaccines
CureVac is also eligible for future royalties. CureVac shares jumped 12% in early trading Wednesday, while GSK’s American depositary receipt slipped 0.2%. Shares of Moderna a leading mRNA vaccine manufacturer, were up 0.9%.
- Zacks
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
- Investor's Business Daily
Pfizer Hits 11-Year Low And Lingers Sideways For Months — Is It Now A Sell?
Pfizer[ticker symb=PFE] stock continues trending sideways after announcing promising updates for two cancer drugs, but also shutting down a gene therapy program. In one study, multiple myeloma patients who received Pfizer's Elrexfio lived for 24.6 months, at the median. Another study tested Adcetris against chemotherapy in patients with a form of lymphoma.
